Filing Details
- Accession Number:
- 0001144204-14-021706
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-04-09 21:00:26
- Reporting Period:
- 2014-04-07
- Filing Date:
- 2014-04-09
- Accepted Time:
- 2014-04-09 21:00:26
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1270073 | Intercept Pharmaceuticals Inc | ICPT | Pharmaceutical Preparations (2834) | 223868459 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1559512 | Luciano Adorini | C/O Intercept Pharmaceuticals, Inc. 450 W. 15Th Street, Suite 505 New York NY 10011 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2014-04-07 | 2,000 | $10.40 | 9,041 | No | 4 | M | Direct | |
Common Stock | Disposition | 2014-04-07 | 500 | $280.00 | 8,541 | No | 4 | S | Direct | |
Common Stock | Disposition | 2014-04-07 | 500 | $283.00 | 8,041 | No | 4 | S | Direct | |
Common Stock | Disposition | 2014-04-07 | 1,000 | $286.30 | 7,041 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Option to purchase Common Stock | Disposition | 2014-04-07 | 2,000 | $0.00 | 2,000 | $10.40 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
2,000 | 2018-01-07 | No | 4 | M | Direct |
Footnotes
- The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 2, 2013.
- All shares underlying this option have fully vested.